Literature DB >> 2281152

Time-dose factors in radiotherapy: a review of the human data.

H D Thames1, S M Bentzen, I Turesson, M Overgaard, W Van den Bogaert.   

Abstract

The values for alpha/beta (fractionation sensitivity, or recovery capacity) for early and late reactions in human normal tissues are consistent with results from experimental animals. For breast treatments direct analysis indicates that for early reactions alpha/beta is in the range 7 to 11 Gy, while for late effects it is in the range 2 to 4 Gy. Data on recovery kinetics in human tissues is limited but these indicate that recovery may be slower in humans than in rodents. For early skin reactions the halftime of recovery is about 1 h, while for late telangiectasia it is more than 3 h. alpha/beta values for human tumors are more variable than in rodents: some are high (head and neck, lung, skin, cervix) and similar to those for early reacting normal tissues. Others are low, including melanomas, where alpha/beta was estimated at 0.6 (-1.1, 2.5) Gy, and liposarcomas, where direct analysis of cases surveyed from the literature suggested that alpha/beta = 0.4 (-1.4, 5.4) Gy. Repopulation kinetics is faster in the mucosa of the soft palate and faucial pillars (1.8 Gy/day) than in head and neck tumors (up to 1 Gy/day).

Entities:  

Mesh:

Year:  1990        PMID: 2281152     DOI: 10.1016/0167-8140(90)90149-q

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  52 in total

1.  Compliance to the prescribed overall treatment time (OTT) of curative radiotherapy in normal clinical practice and impact on treatment duration of counteracting short interruptions by treating patients on Saturdays.

Authors:  M Maciá I Garau; J Solé Monné; M J Cambra Serés; C Monfà Binefa; M Peraire Llopis
Journal:  Clin Transl Oncol       Date:  2009-05       Impact factor: 3.405

2.  A new view of radiation-induced cancer: integrating short- and long-term processes. Part II: second cancer risk estimation.

Authors:  Igor Shuryak; Philip Hahnfeldt; Lynn Hlatky; Rainer K Sachs; David J Brenner
Journal:  Radiat Environ Biophys       Date:  2009-06-05       Impact factor: 1.925

Review 3.  Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.

Authors:  Meghan Campo; Hani Al-Halabi; Melin Khandekar; Alice T Shaw; Lecia V Sequist; Henning Willers
Journal:  Oncologist       Date:  2016-06-27

Review 4.  Linear quadratic and tumour control probability modelling in external beam radiotherapy.

Authors:  S F C O'Rourke; H McAneney; T Hillen
Journal:  J Math Biol       Date:  2008-09-30       Impact factor: 2.259

5.  Investigation of effective decision criteria for multiobjective optimization in IMRT.

Authors:  Clay Holdsworth; Robert D Stewart; Minsun Kim; Jay Liao; Mark H Phillips
Journal:  Med Phys       Date:  2011-06       Impact factor: 4.071

6.  A Retrospective Analysis of Toxicity and Efficacy for 2 Hypofractionated Irradiation Schedules Versus a Conventional One for Post-Mastectomy Adjuvant Radiotherapy in Breast Cancer.

Authors:  Vassilis Kouloulias; Eftychia Mosa; Anna Zygogianni; Efrosini Kypraiou; John Georgakopoulos; Kalliopi Platoni; Christos Antypas; George Kyrgias; Maria Tolia; Christos Papadimitriou; Amanda Psyrri; George Patatoukas; Maria Dilvoi; Christina Armpilia; Kyriaki Theodorou; Maria-Aggeliki Kalogeridi; Ivelina Beli; John Kouvaris; Nikolaos Kelekis
Journal:  Breast Care (Basel)       Date:  2016-09-28       Impact factor: 2.860

7.  Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordoma.

Authors:  M Mima; Y Demizu; D Jin; N Hashimoto; M Takagi; K Terashima; O Fujii; Y Niwa; T Akagi; T Daimon; Y Hishikawa; M Abe; M Murakami; R Sasaki; N Fuwa
Journal:  Br J Radiol       Date:  2013-11-28       Impact factor: 3.039

8.  On the need to compensate for edema-induced dose reductions in preplanned (131)Cs prostate brachytherapy.

Authors:  Z Jay Chen; Jun Deng; Kenneth Roberts; Ravinder Nath
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-05       Impact factor: 7.038

9.  Radiobiological restrictions and tolerance doses of repeated single-fraction hdr-irradiation of intersecting small liver volumes for recurrent hepatic metastases.

Authors:  Ricarda Rühl; Lutz Lüdemann; Anna Czarnecka; Florian Streitparth; Max Seidensticker; Konrad Mohnike; Maciej Pech; Peter Wust; Jens Ricke
Journal:  Radiat Oncol       Date:  2010-05-27       Impact factor: 3.481

10.  Who benefits from hypofractionated radiation therapy for clinically localized prostate cancer: evidence from meta-analysis.

Authors:  Libin Sun; Linbin Sun; Shimiao Zhu; Yang Zhao; Hui Zhang; Zhiqun Shang; Ning Jiang; Gang Li; Yuanjie Niu
Journal:  Tumour Biol       Date:  2014-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.